Impact

A booster dose of MenACYW-TT induces robust immune responses in children and adolescents primed with MenACYW-TT or another MCV4 (MCV4-DT or MCV4-CRM), respectively.Here, we demonstrate that MenACYW-TT booster 3–6 years after primary vaccination induced robust immunogenicity against all serogroups, regardless of the priming vaccine (MenACWY-TT or MCV4-CRM), and was well tolerated.Persistence of the immune response following previous primary vaccination with MenACYW-TT was demonstrated.MenACYW-TT booster with MenB vaccine co-administration did not affect MenACWY-TT immunogenicity and was well tolerated.These findings will facilitate the provision of broader protection against IMD particularly in higher-risk groups such as adolescents.